2024
Inflammasomes in chronic liver disease: Hepatic injury, fibrosis progression and systemic inflammation
Taru V, Szabo G, Mehal W, Reiberger T. Inflammasomes in chronic liver disease: Hepatic injury, fibrosis progression and systemic inflammation. Journal Of Hepatology 2024, 81: 895-910. PMID: 38908436, DOI: 10.1016/j.jhep.2024.06.016.Peer-Reviewed Original ResearchAcute-on-chronic liver failureChronic liver diseaseLiver disease progressionToll-like receptorsLiver diseasePortal hypertensionLiver failureDisease progressionLiver injuryImmune systemEnd-stage liver diseaseRelease of pro-inflammatory cytokinesInnate immune cellsFlares of inflammationDysfunctional immune systemInflammasome activationPro-inflammatory stateNuclear factor kappa BPro-inflammatory cytokinesAdaptive immune systemFactor kappa BSystemic inflammationLiver parenchymal cellsWhite adipose tissueImmune cellsRNA modifications in the progression of liver diseases: from fatty liver to cancer
Li S, Mehal W, Ouyang X. RNA modifications in the progression of liver diseases: from fatty liver to cancer. Science China Life Sciences 2024, 67: 2105-2119. PMID: 38809498, PMCID: PMC11545962, DOI: 10.1007/s11427-023-2494-x.Peer-Reviewed Original ResearchRNA modificationsRNA metabolismRNA speciesNon-alcoholic fatty liver diseaseN1-methyladenosineCellular functionsN6-methyladenosineGene expressionRNANon-alcoholic steatohepatitisFatty liver to non-alcoholic steatohepatitisM6AHepatocellular carcinomaGlobal health concernFatty liver diseaseLiver diseaseM5CHigher risk of metabolic syndromePseudouridineAssociated with higher risk of metabolic syndromePathological conditionsRisk of metabolic syndromeGenes-methyladenosineProgression of liver disease
2023
Bioactive signalling lipids as drivers of chronic liver diseases
Kaffe E, Tisi A, Magkrioti C, Aidinis V, Mehal W, Flavell R, Maccarrone M. Bioactive signalling lipids as drivers of chronic liver diseases. Journal Of Hepatology 2023, 80: 140-154. PMID: 37741346, DOI: 10.1016/j.jhep.2023.08.029.Peer-Reviewed Original ResearchConceptsChronic liver diseaseLiver diseasePrevalent chronic liver diseaseBioactive lipidsPotential therapeutic targetG protein-coupled receptorsProtein-coupled receptorsTherapeutic targetPoly-unsaturated fatty acidsMalignant transformationPotent modulatorEnergy homeostasisDiseaseCell proliferationSignaling lipidsTissue repairReceptorsFatty acidsMultiple cellular functionsLipidsBioactive roleBioactive signaling lipidsInflammationProgression
2022
S1453 Weight Loss in Bariatric Surgery Patients Treated at a Novel Clinic Incorporating Obesity Medicine for Treatment of Nonalcoholic Fatty Liver Disease
Ilagan-Ying Y, Schwartz A, Park E, Bollinger B, Ying L, Mehal W, Do A. S1453 Weight Loss in Bariatric Surgery Patients Treated at a Novel Clinic Incorporating Obesity Medicine for Treatment of Nonalcoholic Fatty Liver Disease. The American Journal Of Gastroenterology 2022, 117: e1043-e1044. DOI: 10.14309/01.ajg.0000862452.53915.0f.Peer-Reviewed Original Research
2020
Nonalcoholic Fatty Liver Disease in the Post Liver Transplant Patient
Batisti J, Mehal W. Nonalcoholic Fatty Liver Disease in the Post Liver Transplant Patient. Current Transplantation Reports 2020, 7: 332-339. DOI: 10.1007/s40472-020-00303-0.Peer-Reviewed Original ResearchFatty liver diseaseLiver transplantNonalcoholic steatohepatitisLiver diseasePost liver transplant patientsReviewNonalcoholic fatty liver diseaseNonalcoholic fatty liver diseaseManagement of immunosuppressionManagement of NAFLDPost-transplant populationLiver transplant patientsPost-transplant periodExcess weight gainRecent FindingsRecent studiesGraft steatosisNAFLD interventionGraft fibrosisHepatic manifestationRecurrent diseaseTransplant patientsMetabolic syndromeMedical managementRecipient factorsInsulin resistanceLT populationS1189 Incorporation of Obesity Medicine Into the Care of Patients With Nonalcoholic Fatty Liver Disease: 1-Year Interim Results
Mankash M, Kelly M, Duffy A, Mehal W, Do A. S1189 Incorporation of Obesity Medicine Into the Care of Patients With Nonalcoholic Fatty Liver Disease: 1-Year Interim Results. The American Journal Of Gastroenterology 2020, 115: s595-s595. DOI: 10.14309/01.ajg.0000706804.10023.a3.Peer-Reviewed Original Research
2019
Medical Approach for Weight Loss in Nonalcoholic Fatty Liver Disease
Do A, Ilagan-Ying Y, Mehal W. Medical Approach for Weight Loss in Nonalcoholic Fatty Liver Disease. Current Hepatology Reports 2019, 18: 444-454. DOI: 10.1007/s11901-019-00498-6.Peer-Reviewed Original ResearchSuccessful weight lossFatty liver diseaseWeight lossLiver diseaseReviewNonalcoholic fatty liver diseaseNonalcoholic fatty liver diseaseWeight loss medicationsCurrent medical therapyPatient-centered approachMedical therapyPatient weightPatient evaluationMultisystemic complicationsEpidemic proportionsBehavioral change goalsNAFLDMedical approachObesityDiseaseMedicationsMultimodal approachFibrosisTreatmentSteatosisComplicationsThe impact of scoring system in the evaluation of Nonalcoholic fatty liver disease (NAFLD) and nonalcoholic steatohepatitis (NASH)
Yousaf M, Chaudhary F, Mehal W. The impact of scoring system in the evaluation of Nonalcoholic fatty liver disease (NAFLD) and nonalcoholic steatohepatitis (NASH). Gastroenterology & Hepatology Open Access 2019, 10: 262-266. DOI: 10.15406/ghoa.2019.10.00392.Peer-Reviewed Original Research1056 Incorporation of Obesity Management into the Care of Patients With Nonalcoholic Steatohepatitis: The Yale Fatty Liver Disease Model
Mankash M, Kelly M, Dean J, Duffy A, Mehal W, Do A. 1056 Incorporation of Obesity Management into the Care of Patients With Nonalcoholic Steatohepatitis: The Yale Fatty Liver Disease Model. The American Journal Of Gastroenterology 2019, 114: s599-s599. DOI: 10.14309/01.ajg.0000593756.22484.ae.Peer-Reviewed Original ResearchNonalcoholic fatty liver diseaseWeight loss medicationsNonalcoholic steatohepatitisBariatric surgeryWeight lossClinical characteristicsLiver diseaseObesity managementEffective treatmentDisease programsAverage age 55Meal replacement therapySurgical weight lossWeight loss optionsAlanine aminotransferase levelsChronic liver diseaseFatty liver diseaseObstructive sleep apneaManagement of patientsCare of patientsLimited efficacy dataClinical care modelsLiver disease modelAverage weight lossHepatology clinicIncorporating Weight Loss Medications Into Hepatology Practice for Nonalcoholic Steatohepatitis
Do A, Kuszewski EJ, Langberg K, Mehal W. Incorporating Weight Loss Medications Into Hepatology Practice for Nonalcoholic Steatohepatitis. Hepatology 2019, 70: 1443-1456. PMID: 30991446, PMCID: PMC6783325, DOI: 10.1002/hep.30658.Peer-Reviewed Original ResearchConceptsTotal body weight lossWeight loss medicationsNonalcoholic steatohepatitisHepatology clinicStaging of NASHPartial histological responseBody weight lossHepatology practiceNASH histologyLiver histologyClinical profileLiver diseaseLiver triglyceridesNew medicationsClinical trialsHistological responseLifestyle changesPatientsMedicationsUncommonly resultsNatural historyClinical interventionsWeight lossSteatohepatitisHepatologists
2018
Role of sterile inflammation in fatty liver diseases
Chen Y, Yousaf M, Mehal W. Role of sterile inflammation in fatty liver diseases. Liver Research 2018, 2: 21-29. DOI: 10.1016/j.livres.2018.02.003.Peer-Reviewed Original ResearchNon-alcoholic steatohepatitisSterile inflammationInflammatory responseTissue damageRegulatory T cellsFatty liver diseaseAnti-inflammatory effectsHepatic inflammatory responseAcute phase reactantsHigh-fat dietPropagation of inflammationSinusoidal endothelial cellsPro-inflammatory damageTrans retinoic acidGrowth factor βLiver inflammationMetabolic syndromeLiver diseaseIL-1βInflammatory cytokinesFat dietAlcohol excessFemale micePhase reactantsT cellsDigoxin Suppresses Pyruvate Kinase M2-Promoted HIF-1α Transactivation in Steatohepatitis
Ouyang X, Han SN, Zhang JY, Dioletis E, Nemeth BT, Pacher P, Feng D, Bataller R, Cabezas J, Stärkel P, Caballeria J, Pongratz RL, Cai SY, Schnabl B, Hoque R, Chen Y, Yang WH, Garcia-Martinez I, Wang FS, Gao B, Torok NJ, Kibbey RG, Mehal WZ. Digoxin Suppresses Pyruvate Kinase M2-Promoted HIF-1α Transactivation in Steatohepatitis. Cell Metabolism 2018, 27: 339-350.e3. PMID: 29414684, PMCID: PMC5806149, DOI: 10.1016/j.cmet.2018.01.007.Peer-Reviewed Original ResearchMeSH KeywordsAmino Acid SequenceAnimalsCell NucleusChromatinDigoxinDisease Models, AnimalEndotoxinsHistonesHumansHypoxia-Inducible Factor 1, alpha SubunitInflammationLiverNon-alcoholic Fatty Liver DiseaseOxidation-ReductionProtein BindingPyruvate KinaseTHP-1 CellsTranscription, GeneticTranscriptional ActivationConceptsHIF-1α transactivationSterile inflammationHIF-1α pathway activationNon-alcoholic steatohepatitisKinase M2Major clinical consequencesAbility of digoxinLiver inflammationLiver diseasePyruvate kinase M2Clinical consequencesTherapeutic targetInflammationTissue damageHIF-1αPathway activationDigoxinOxidative stressCardiac glycosidesSteatohepatitisDigoxin bindsNovel roleLiverUbiquitous responseActivation
2013
The Immunopathogenesis of Cirrhosis
Gao B, Friedman S, Mehal W. The Immunopathogenesis of Cirrhosis. 2013, 413-424. DOI: 10.1007/978-3-319-02096-9_28.Peer-Reviewed Original ResearchHepatocellular carcinomaProgressive liver injuryChronic liver diseaseNatural killer cellsImmune cell subsetsAltered hepatic functionInnate immune responseWound healing responseViral hepatitisLiver injuryFibrosis progressionKiller cellsLiver diseaseAutoimmune diseasesCell subsetsChronic injuryHepatic fibrosisFibrogenic responseFibrosis resolutionHepatic functionHepatic parenchymaVascular remodelingImmune responseHepatocellular apoptosisBlood flow
2012
Sterile Inflammation in the Liver
Kubes P, Mehal WZ. Sterile Inflammation in the Liver. Gastroenterology 2012, 143: 1158-1172. PMID: 22982943, DOI: 10.1053/j.gastro.2012.09.008.Peer-Reviewed Original ResearchMeSH KeywordsAcetaminophenAdenosine TriphosphateCaspase 1Chemical and Drug Induced Liver InjuryChemotaxis, LeukocyteCytokinesFatty LiverFatty Liver, AlcoholicHepatitisHMGB1 ProteinHumansInflammasomesInterleukin-1betaNeutrophilsNon-alcoholic Fatty Liver DiseaseNucleic AcidsReceptors, Pattern RecognitionReperfusion InjurySignal TransductionUric AcidConceptsDamage-associated molecular patternsPattern recognition receptorsImmune cellsSterile inflammationRecognition receptorsCellular pattern recognition receptorsDrug-induced liver injuryEndogenous damage-associated molecular patternsSuch damage-associated molecular patternsMolecular patternsSite of injuryPathogen-associated molecular patternsProtease caspase-1Alcoholic steatohepatitisLiver injuryNonalcoholic steatohepatitisLiver diseaseProinflammatory cytokinesSpecific therapyInterleukin-1βLiver pathologyTissue injuryImmune responseTherapeutic targetActivate receptors
2007
The Role of Inflammation and Immunity in the Pathogenesis of Liver Fibrosis
Mehal W, Friedman S. The Role of Inflammation and Immunity in the Pathogenesis of Liver Fibrosis. 2007, 111-121. DOI: 10.1007/978-1-59745-518-3_10.Peer-Reviewed Original ResearchHepatic fibrosisChronic liver diseaseRole of inflammationWound healing responseViral hepatitisLiver diseaseFibrosis progressionAutoimmune diseasesChronic injuryLiver fibrosisCellular sourceFibrosisExtracellular matrixDiseaseRealistic expectationsUbiquitous responseMajor advancesTranscriptional eventsHepatitisInflammationPatientsPathophysiologyPathogenesisInjuryLiver